Please complete Pre-test

Chapter 1 of 1

 

 

Release Date: October 30, 2017
Expiration Date: October 30, 2018

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

There is a significant unmet need in existing treatment paradigms for patients with acute myeloid leukemia (AML) due to poor survival and intolerability to cytotoxic chemotherapy, especially for a generally older patient population. Hypomethylating agents (HMAs) have demonstrated a benefit in patients with AML, especially those who require less aggressive therapy, but there is a need for improved efficacy and survival outcomes. In this activity, participants will learn about HMAs in existing treatment paradigms, as well as the investigational landscape of novel therapies in combination with HMAs, and their potential impact on treatment outcomes for patients with AML.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the current role of hypomethylating agents (HMAs) in existing treatment paradigms and specific patient populations
  • Summarize safety and efficacy data from key clinical trials investigating novel agents in combination with HMAs for patients with AML
  • Identify clinical trials with active or planned enrollment of patients with AML that are investigating combination therapy with an HMA

Agenda

Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents – Ehab Atallah, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 30, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Ehab Atallah, MD
Associate Professor of Medicine
Medical College of Wisconsin
Division of Hematology and Oncology
Milwaukee, Wisconsin

Dr. Ehab Atallah received his medical degree from Cairo University School of Medicine. He completed an internal medicine residency in the Cleveland Clinic Health System, a fellowship in hematology/oncology at the Karmanos Cancer Center, where he served as chief fellow, as well as a leukemia fellowship at MD Anderson Cancer Center. Dr. Atallah is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital.

Dr. Atallah is board certified in internal medicine, medical oncology, and hematology. He has authored numerous publications, including journal articles and meeting abstracts. His current research interests include the treatment of patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myelogenous leukemia, myeloproliferative neoplasms, and myelodysplastic syndromes.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.



©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-178-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Ehab Atallah has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.